IN8bio reports 100% AML remission with INB-100; FDA guidance for registrational trial

IN8BIO, INC.

100% of AML patients in Phase 1 trial remain in complete remission; all relapse-free beyond one year.
Received FDA guidance for registrational trial of INB-100 in AML; IND submission planned Q1 2025.
INB-200 for GBM shows prolonged survival in higher dose cohorts; one MGMT-unmethylated patient in remission >1 year.
No new relapses since May 15, 2024; safety manageable with no significant cell therapy-related toxicities.
INB-400 Phase 2 trial for front-line GBM actively enrolling at multiple US sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.